RxDoctor Payments Data

James Lennon, DO

Hematology & Oncology · Opelika, ALNPI 1124339338

Payments from drug & device makers

$6,805in general payments, 2019–2025

Across 163 payments — averaging $41.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Deciphera Pharmaceuticals Inc.$2K
  • Jazz Pharmaceuticals Inc.$1K
  • AstraZeneca$329
  • Bristol Myers Squibb$251
  • Daiichi Sankyo Inc.$217
  • Merck$214
  • plus $3K from 37 others

What the payments were for

  • Consulting fees$3,25048%
  • Speaking & faculty fees$1502%
  • Food & beverage$3,30749%
  • Education$981%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,805 in reported general payments places this provider in the 35th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama

Medicare billing

Part B allowed, 2024
$47,457
Medicare patients
121
Services billed
457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide62$839,877
RevlimidLenalidomide19$330,452
CalquenceAcalabrutinib Maleate21$306,549
ErleadaApalutamide20$280,573
VerzenioAbemaciclib19$275,146
ImbruvicaIbrutinib19$262,648
TagrissoOsimertinib Mesylate12$197,251
Lenalidomide21$191,509
Abiraterone Acetate13$30,225
EliquisApixaban29$16,711
Enoxaparin Sodium14$5,888
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen70$1,748
Morphine Sulfate ErMorphine Sulfate48$1,315
Megestrol Acetate15$1,280
Acyclovir35$1,004

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence, Tagrisso$329$503,80033 claims
Bristol Myers SquibbRevlimid$251$330,45219 claims
Johnson & JohnsonErleada$148$280,57320 claims
Lilly USA, LLCVerzenio, Olanzapine$36$275,41133 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$23$262,64819 claims
PfizerEliquis$193$16,71129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 177 hematology & oncology providers in Alabama.

Other hematology & oncology in Opelika

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →